Addex Therapeutics Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Addex Therapeutics şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-4.3%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-4.3%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Increases to CEO Compensation Might Be Put On Hold For Now at Addex Therapeutics Ltd (VTX:ADXN)

Jun 10

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: ADXN şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: ADXN şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Addex Therapeutics Piyasaya Karşı Temettü Getirisi

ADXN temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (ADXN)	n/a
Pazarın Alt %25'i (CH)	2.0%
Pazarın En İyi %25'i (CH)	4.5%
Sektör Ortalaması (Biotechs)	1.6%
Analist tahmini (ADXN) (3 yıla kadar)	0%

Önemli Temettü: ADXN şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, ADXN şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: ADXN şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: ADXN herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Addex Therapeutics Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

New major risk - Revenue size

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Addex Therapeutics Ltd to Report First Half, 2024 Results on Sep 16, 2024

Addex Therapeutics Ltd and Indivior PLC Selects Clinical Candidates from Gabab Positive Allosteric Modulator Research Collaboration

Addex Therapeutics Ltd Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium

New major risk - Financial position

Addex Therapeutics Ltd, Annual General Meeting, Jun 28, 2024

No longer forecast to breakeven

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Revenue and earnings growth

No longer forecast to breakeven

Addex Therapeutics Ltd to Report Fiscal Year 2023 Results on Apr 18, 2024

Addex Therapeutics Announces the Launch of Neurosterix, Company Focused on Developing Allosteric Modulators for the Treatment of Underserved Neurological Disorders

New major risk - Shareholder dilution

Addex Therapeutics Ltd has filed a Follow-on Equity Offering in the amount of $2.15 million.

Addex Therapeutics Ltd to Report Q3, 2024 Results on Nov 11, 2024

Co-Founder recently bought CHF911k worth of stock

Third quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Addex Therapeutics' ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients

Addex Regains Nasdaq Listing Compliance

New minor risk - Profitability

Consensus revenue estimates increase by 31%

Addex Therapeutics Announces Data Published in Brain

New major risk - Market cap size

Second quarter 2023 earnings released: CHF0.04 loss per share (vs CHF0.19 loss in 2Q 2022)

Addex Therapeutics Ltd announced that it has received CHF 2.7 million in funding from Indivior PLC

Addex mGlu2PAM Demonstrates Potential in Substance Use Disorder

Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

First quarter 2023 earnings released: CHF0.04 loss per share (vs CHF0.15 loss in 1Q 2022)

Addex Therapeutics Announces ADX71149 Phase 2 Epilepsy Clinical Study’s Independent Interim Review Committee Recommends Continuing Study

Insufficient new directors

No longer forecast to breakeven

Here's Why Addex Therapeutics (VTX:ADXN) Must Use Its Cash Wisely

Addex Regains Nasdaq Listing Compliance

Addex Therapeutics Ltd to Report Fiscal Year 2022 Results on Mar 13, 2023

No longer forecast to breakeven

Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Consensus revenue estimates fall by 27%

Addex Therapeutics Ltd announced that it has received funding from Armistice Capital LLC

Addex Therapeutics Ltd announced that it expects to receive funding from Armistice Capital LLC

No longer forecast to breakeven

Consensus forecasts updated

Addex Terminates Dipraglurant Phase 2b/3 Study in Patients with Dyskinesia Associated with Parkinson's Disease due to Slow Recruitment Rate

Consensus forecasts updated

Addex Therapeutics Ltd Provides Update on Dipraglurant Blepharospasm Phase 2 Feasibility Clinical Study

No longer forecast to breakeven

Here's Why Addex Therapeutics (VTX:ADXN) Must Use Its Cash Wisely

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to CHF1.40

Forecast to breakeven in 2024

Addex Therapeutics Ltd Completes Patient Enrollment for Dipraglurant Blepharospasm Phase 2 Clinical Study

Addex Therapeutics Ltd Expands Pipeline with Selective M4 Positive Allosteric Modulator Program

Addex Therapeutics Ltd, Annual General Meeting, May 09, 2022

Addex Therapeutics Ltd, Annual General Meeting, May 09, 2022

Consensus revenue estimates fall by 64%

Price target decreased to CHF1.40

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Forecast to breakeven in 2023

Addex Therapeutics Ltd announced that it has received CHF 5.427937 million in funding from Armistice Capital LLC

Addex Therapeutics Ltd announced that it expects to receive CHF 5.427937 million in funding from Armistice Capital LLC

Is Addex Therapeutics (VTX:ADXN) In A Good Position To Invest In Growth?

Third quarter 2021 earnings released: CHF0.11 loss per share (vs CHF0.12 loss in 3Q 2020)

Addex Therapeutics Ltd Initiates Phase 2 Clinical Study with Dipraglurant in Blepharospasm

Director Jason Nunn has joined 5th company board

Director Jason Nunn has joined 5th company board

Director Jason Nunn has joined 5th company board

Director Jason Nunn has joined 5th company board

Second quarter 2021 earnings released: CHF0.14 loss per share (vs CHF0.12 loss in 2Q 2020)

Increases to CEO Compensation Might Be Put On Hold For Now at Addex Therapeutics Ltd (VTX:ADXN)

Addex Therapeutics Starts Phase 2 Clinical Study of ADX71149 for Epilepsy

Addex's Dipraglurant Restores Synaptic Plasticity in Models of Dystonia

Consensus forecasts updated

First quarter 2021 earnings released: CHF0.08 loss per share (vs CHF0.16 loss in 1Q 2020)

Consensus revenue estimates increase to CHF3.90m

Ödemelerde İstikrar ve Büyüme